The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study
Abstract
:1. Introduction
2. Results
2.1. Sociodemographic and Clinical Characteristics at Study Inclusion
2.2. Comparative Analysis of Antiretroviral Therapy Regimens and Treatment Response
2.3. Impact of Antiretroviral Treatment Experience on Immune and Virologic Outcomes
2.4. Regression Analysis of Predictive Factors for Immune and Virologic Status
2.5. Comparative Analysis of Liver and Pancreatic Function
2.6. Risk Estimation for Liver Dysfunction Associated with Coinfections
3. Discussion
4. Materials and Methods
4.1. Study Design
4.2. Clinical and Biochemical Determinations
4.3. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
ABC | Abacavir |
ALP | Alkaline phosphatase |
ALT | Alanine aminotransferase |
ARV | Antiretroviral |
AST | Aspartate transaminase |
B | Bictegravir |
COBI | Cobicistat |
DILI | Drug-induced liver damage |
DRV | Darunavir |
DTG | Dolutegravir |
EFZ | Efavirenz |
EI | Entry inhibitor |
ETV | Etravirine |
FTC | Emtricitabine |
FDA | U.S. Food and Drug Administration |
GGT | Gamma-glutamyl transferase |
HAART | Highly active antiretroviral therapy |
HBsAg | Hepatitis B surface antigen |
HBV | Hepatitis B virus |
HCV | Hepatitis c virus |
HIV | Human immunodeficiency virus |
II | Integrase inhibitor |
INSTI | Integrase strand transfer inhibitors |
IU | International units |
3TC | Lamivudine |
LFT | Liver function test |
MSM | Men who have sex with men |
NAFLD | Non-alcoholic fatty liver disease |
NIID MB | National Institute of Infectious Diseases “Prof. Dr. Matei Balș” |
NNRTI | Non-nucleoside reverse transcriptase inhibitor |
NRTI | Nucleoside reverse transcriptase inhibitor |
PCR | Real-time polymerase chain reaction |
PI | Protease inhibitor |
PLWH | People living with HIV |
PWIDs | People who inject drugs |
RAL | Raltegravir |
RTV | Ritonavir |
RNA | Ribonucleic acid |
TAF | Tenofovir alafenamide |
TDF | Tenofovir disoproxil fumarate |
ZDV | Zidovudine |
References
- Hagos, Y.M.; Yalew, G.T.; Meles, H.N.; Tsegay, E.; Lemelem, M.; Wasihun, A.G. Hepatitis B and C Viral Coinfection and Associated Factors among HIV-Positive Patients Attending ART Clinics of Afar Regional State, Northeast Ethiopia. PLoS ONE 2024, 19, e0302453. [Google Scholar] [CrossRef]
- Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Available online: https://www.who.int/publications/i/item/9789240091672 (accessed on 29 March 2025).
- Global Burden of Hepatitis B Infection in People Living with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/31813969/ (accessed on 29 March 2025).
- Spradling, P.R.; Richardson, J.T.; Buchacz, K.; Moorman, A.C.; Brooks, J.T. HIV Outpatient Study (HOPS) Investigators Prevalence of Chronic Hepatitis B Virus Infection among Patients in the HIV Outpatient Study, 1996–2007. J. Viral Hepat. 2010, 17, 879–886. [Google Scholar] [CrossRef]
- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Available online: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/hepatitis-b-virus-hiv-coinfection (accessed on 29 March 2025).
- Jin, F.; Dore, G.J.; Matthews, G.; Luhmann, N.; Macdonald, V.; Bajis, S.; Baggaley, R.; Mathers, B.; Verster, A.; Grulich, A.E. Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. Lancet Gastroenterol. Hepatol. 2021, 6, 39–56. [Google Scholar] [CrossRef]
- Alter, M.J. Epidemiology of Viral Hepatitis and HIV Co-Infection. J. Hepatol. 2006, 44, S6–S9. [Google Scholar] [CrossRef] [PubMed]
- Zarębska-Michaluk, D.; Rzymski, P.; Kanecki, K.; Tyszko, P.; Lewtak, K.; Goryński, P.; Genowska, A.; Parczewski, M.; Flisiak, R. Hospitalizations and Deaths among People Coinfected with HIV and HCV. Sci. Rep. 2024, 14, 28586. [Google Scholar] [CrossRef]
- Aranzabal, L.; Casado, J.L.; Moya, J.; Quereda, C.; Diz, S.; Moreno, A.; Moreno, L.; Antela, A.; Perez-Elias, M.J.; Dronda, F.; et al. Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy-Associated Hepatotoxicity in Patients with HIV and Hepatitis C Virus Coinfection. Clin. Infect. Dis. 2005, 40, 588–593. [Google Scholar] [CrossRef] [PubMed]
- Labarga, P.; Soriano, V.; Vispo, M.E.; Pinilla, J.; Martin-Carbonero, L.; Castellares, C.; Casado, R.; Maida, I.; Garcia-Gasco, P.; Barreiro, P. Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. J. Infect. Dis. 2007, 196, 670–676. [Google Scholar] [CrossRef] [PubMed]
- Side Effects of HIV Medicines HIV and Hepatotoxicity | NIH. Available online: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-hepatotoxicity (accessed on 29 March 2025).
- Kwofie, T.B.; Adigbli, D.; Osei-Yeboah, J.; Ativi, E.; Lokpo, S.Y. Hepatitis B and C Infections in HIV-1 Patients on Combination Antiretroviral Therapy (cART) in Ghana: Implications for Immunologic Recovery, Clinical Response to Treatment, and Hepatotoxicity. Heliyon 2021, 7, e07172. [Google Scholar] [CrossRef]
- Taylor, L.E.; Swan, T.; Mayer, K.H. HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms. Clin. Infect. Dis. 2012, 55 (Suppl. S1), S33–S42. [Google Scholar] [CrossRef]
- de Vries-Sluijs, T.E.M.S.; Reijnders, J.G.P.; Hansen, B.E.; Zaaijer, H.L.; Prins, J.M.; Pas, S.D.; Schutten, M.; Hoepelman, A.I.M.; Richter, C.; Mulder, J.W.; et al. Long-Term Therapy with Tenofovir Is Effective for Patients Co-Infected with Human Immunodeficiency Virus and Hepatitis B Virus. Gastroenterology 2010, 139, 1934–1941. [Google Scholar] [CrossRef]
- Bersoff-Matcha, S.J.; Cao, K.; Jason, M.; Ajao, A.; Jones, S.C.; Meyer, T.; Brinker, A. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann. Intern. Med. 2017, 166, 792–798. [Google Scholar] [CrossRef] [PubMed]
- Klein, M.B.; Althoff, K.N.; Jing, Y.; Lau, B.; Kitahata, M.; Lo Re, V.; Kirk, G.D.; Hull, M.; Kim, H.N.; Sebastiani, G.; et al. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin. Infect. Dis. 2016, 63, 1160–1167. [Google Scholar] [CrossRef]
- da Silva, C.M.; de Peder, L.D.; Guelere, A.M.; Horvath, J.D.; Silva, E.S.; Teixeira, J.J.V.; Bertolini, D.A. Seroprevalence of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) among Human Immunodeficiency Virus (HIV)-Infected Patients in an HBV Endemic Area in Brazil. PLoS ONE 2018, 13, e0203272. [Google Scholar] [CrossRef]
- Compartimentul Pentru Monitorizarea și Evaluarea Infecției Hiv/Sida în România Institutul Național de Boli Infecțioase “Prof. Dr. Matei Balș”. Available online: https://cnlas.ro/ (accessed on 29 March 2025).
- Hohan, R.; Paraschiv, S.; Nicolae, I.; Oțelea, D. Estimating the Current Routes of Transmission in HIV-1 F1 Subtype Infected Persons in Romania: Differences Between Self-Reporting and Phylogenetic Data. Pathogens 2024, 13, 960. [Google Scholar] [CrossRef]
- Curici, A.; Ilie, O.M.; Mindru, D.E. Prevalence of HDV, HCV, and HIV Infection in the Population of Patients Infected with HBV in a Romanian Cohort. Microorganisms 2025, 13, 118. [Google Scholar] [CrossRef] [PubMed]
- Paraschiv, S.; Banica, L.; Nicolae, I.; Niculescu, I.; Abagiu, A.; Jipa, R.; Pineda-Peña, A.-C.; Pingarilho, M.; Neaga, E.; Theys, K.; et al. Epidemic Dispersion of HIV and HCV in a Population of Co-Infected Romanian Injecting Drug Users. PLoS ONE 2017, 12, e0185866. [Google Scholar] [CrossRef]
- Lincoln, D.; Petoumenos, K.; Dore, G.J.; Australian HIV Observational Database. HIV/HBV and HIV/HCV Coinfection, and Outcomes Following Highly Active Antiretroviral Therapy. HIV Med. 2003, 4, 241–249. [Google Scholar] [CrossRef]
- Jaggu, R.A.; Eseohe, M.B.; Ogu, A.C.; Jaggu, A.Y.; Ishaleku, D.; Akyala, A.I. Viral Hepatitis Co-Infection Impact on Response to Antiretroviral Therapy and HIV Disease Progression: Virologic and Immunological Indices Outlook. Biomed. Sci. 2021, 7, 124–130. [Google Scholar] [CrossRef]
- Jia, J.; Zhu, Q.; Deng, L.; Lan, G.; Johnson, A.; Chen, H.; Shen, Z.; Li, J.; Xing, H.; Ruan, Y.; et al. Treatment Outcomes of HIV Patients with Hepatitis B and C Virus Co-Infections in Southwest China: An Observational Cohort Study. Infect. Dis. Poverty 2022, 11, 7. [Google Scholar] [CrossRef]
- What’s New: Adult and Adolescent ARV HIV Clinical Guidelines | NIH. Available online: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new (accessed on 29 March 2025).
- Streinu-Cercel, A.; Săndulescu, O.; Poiană, C.; Dorobanţu, M.; Mircescu, G.; Lăzureanu, V.E.; Dumitru, I.-M.; Chirilă, O.; Streinu-Cercel, A. Consensus Statement on the Assessment of Comorbidities in People Living with HIV in Romania. Germs 2019, 9, 198–210. [Google Scholar] [CrossRef]
- Seyoum, E.; Demissie, M.; Worku, A.; Mihret, A.; Abdissa, A.; Berhane, Y. Retention on Antiretroviral Therapy in Person with HIV and Viral Hepatitis Coinfection in Ethiopia: A Retrospective Cohort Study. BMC Public Health 2022, 22, 644. [Google Scholar] [CrossRef] [PubMed]
- Avihingsanon, A.; Lu, H.; Leong, C.L.; Hung, C.-C.; Koenig, E.; Kiertiburanakul, S.; Lee, M.-P.; Supparatpinyo, K.; Zhang, F.; Rahman, S.; et al. Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 and Hepatitis B Coinfection (ALLIANCE): A Double-Blind, Multicentre, Randomised Controlled, Phase 3 Non-Inferiority Trial. Lancet HIV 2023, 10, e640–e652. [Google Scholar] [CrossRef]
- Hurbans, N.; Naidoo, P. Efficacy, Safety, and Tolerability of Dolutegravir-Based ART Regimen in Durban, South Africa: A Cohort Study. BMC Infect. Dis. 2024, 24, 343. [Google Scholar] [CrossRef]
- Wu, X.; Wu, G.; Ma, P.; Wang, R.; Li, L.; Chen, Y.; Xu, J.; Li, Y.; Li, Q.; Yang, Y.; et al. Associations of Modern Initial Antiretroviral Therapy Regimens with All-Cause Mortality in People Living with HIV in Resource-Limited Settings: A Retrospective Multicenter Cohort Study in China. Nat. Commun. 2023, 14, 5334. [Google Scholar] [CrossRef]
- Rancan, I.; Cassol, C.; Graziani, L.; Tilli, M.; Malcontenti, C.; Russo, C.; Bottanelli, M.; Bracchitta, F.; Papaioannu, R.; Labate, L.; et al. Trend over Time of HIV-1 Drug Resistance to Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Their Drivers: A Cohort Study from Antiviral Response Cohort Analysis (ARCA). HIV Med. 2023, 24, 1150–1157. [Google Scholar] [CrossRef]
- Chen, G.-J.; Cheng, C.-Y.; Yang, C.-J.; Lee, N.-Y.; Tang, H.-J.; Huang, S.-H.; Huang, M.-H.; Liou, B.-H.; Lee, Y.-C.; Lin, C.-Y.; et al. Trends of Pre-Treatment Drug Resistance in Antiretroviral-Naïve People with HIV-1 in the Era of Second-Generation Integrase Strand-Transfer Inhibitors in Taiwan. J. Antimicrob. Chemother. 2024, 79, 1157–1163. [Google Scholar] [CrossRef] [PubMed]
- Hui, L.; Xiaoxu, H.; Yuqi, W.; Peng, W.; Xin, W.; Yunyun, Y.; Xin, L. Effectiveness and Safety Analysis of PIs/r Based Dual Therapy in Treatment-Naïve, HIV/AIDS Patients: A Network Meta Analysis of Randomized Controlled Trials. Front. Pharmacol. 2022, 13, 811357. [Google Scholar] [CrossRef] [PubMed]
- Papa, N.; Cammarota, S.; Citarella, A.; Atripaldi, L.; Bernardi, F.F.; Fogliasecca, M.; Giugliano, N.; Trama, U.; Spatarella, M. Evolution in Real-World Therapeutic Strategies for HIV Treatment: A Retrospective Study in Southern Italy, 2014–2020. J. Clin. Med. 2021, 11, 161. [Google Scholar] [CrossRef]
- Elenkov, I.; Nikolova, M.; Radeva, I.; Yankova, M.; Yancheva, N. Immunological Effect of Ten-Year c-ART in Treatment-Naive and Pre-Treated HIV-1 Patients in Bulgaria. Retrovirology 2012, 9, P12. [Google Scholar] [CrossRef]
- Zhao, H.; Feng, A.; Luo, D.; Yuan, T.; Lin, Y.-F.; Ling, X.; Zhong, H.; Li, J.; Li, L.; Zou, H. Factors Associated with Immunological Non-Response after ART Initiation: A Retrospective Observational Cohort Study. BMC Infect. Dis. 2024, 24, 138. [Google Scholar] [CrossRef]
- Perez-Molina, J.A.; Crespillo-Andújar, C.; Zamora, J.; Fernández-Félix, B.M.; Gaetano-Gil, A.; López-Bernaldo de Quirós, J.C.; Serrano-Villar, S.; Moreno, S.; Álvarez-Díaz, N.; Berenguer, J. Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2023, 76, 2027–2037. [Google Scholar] [CrossRef] [PubMed]
- Olawumi, H.; Olanrewaju, D.; Shittu, A.; Durotoye, I.; Akande, A.; Nyamngee, A. Effect of Hepatitis-B Virus Co-Infection on CD4 Cell Count and Liver Function of HIV Infected Patients. Ghana. Med. J. 2014, 48, 96–100. [Google Scholar] [CrossRef]
- da Silva, C.M.; de Peder, L.D.; Silva, E.S.; Previdelli, I.; Pereira, O.C.N.; Teixeira, J.J.V.; Bertolini, D.A. Impact of HBV and HCV Coinfection on CD4 Cells among HIV-Infected Patients: A Longitudinal Retrospective Study. J. Infect. Dev. Ctries. 2018, 12, 1009–1018. [Google Scholar] [CrossRef] [PubMed]
- Bischoff, J.; Mauss, S.; Cordes, C.; Lutz, T.; Scholten, S.; Cornberg, M.; Manns, M.P.; Baumgarten, A.; Rockstroh, J.K. Impact of CD4+ Blood Cell Count and HIV Viral Load on Treatment Response with Direct Acting Antivirals in HIV and HCV Coinfected Patients: Insights from the German Hepatitis C-Registry. HIV Clin. Trials 2018, 19, 225–234. [Google Scholar] [CrossRef] [PubMed]
- Bruix, J. Endpoints in Clinical Trials for Liver Cancer and Their Value in Evidence-Based Clinical Decision Making: An Unresolved Gordian Knot. J. Hepatol. 2021, 74, 1483–1488. [Google Scholar] [CrossRef]
- Kamal, H.; Fornes, R.; Simin, J.; Stål, P.; Duberg, A.-S.; Brusselaers, N.; Aleman, S. Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies. J. Viral Hepat. 2021, 28, 1431–1442. [Google Scholar] [CrossRef]
- Neff, G.W.; Jayaweera, D.; Sherman, K.E. Drug-Induced Liver Injury in HIV Patients. Gastroenterol. Hepatol. 2006, 2, 430–437. [Google Scholar]
- Hu, J.; Liu, K.; Luo, J. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Treat. Res. 2019, 177, 231–250. [Google Scholar] [CrossRef]
- Emery, J.; Pick, N.; Mills, E.J.; Cooper, C.L. Gender Differences in Clinical, Immunological, and Virological Outcomes in Highly Active Antiretroviral-Treated HIV–HCV Coinfected Patients. Patient Prefer. Adherence 2010, 4, 97–103. [Google Scholar]
- den Brinker, M.; Wit, F.W.; Wertheim-van Dillen, P.M.; Jurriaans, S.; Weel, J.; van Leeuwen, R.; Pakker, N.G.; Reiss, P.; Danner, S.A.; Weverling, G.J.; et al. Hepatitis B and C Virus Co-Infection and the Risk for Hepatotoxicity of Highly Active Antiretroviral Therapy in HIV-1 Infection. AIDS 2000, 14, 2895–2902. [Google Scholar] [CrossRef]
- Marin, R.-C.; Tiț, D.M.; Săndulescu, O.; Streinu-Cercel, A.; Bungău, S.G. Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients. Biomedicines 2021, 9, 987. [Google Scholar] [CrossRef]
- Tien, P.C.; Schneider, M.F.; Cole, S.R.; Cohen, M.H.; Glesby, M.J.; Lazar, J.; Young, M.; Mack, W.; Hodis, H.N.; Kaplan, R.C. Association of Hepatitis C Virus and HIV Infection with Subclinical Atherosclerosis in the Women’s Interagency HIV Study. AIDS 2009, 23, 1781–1784. [Google Scholar] [CrossRef]
- Lagathu, C.; Cossarizza, A.; Béréziat, V.; Nasi, M.; Capeau, J.; Pinti, M. Basic Science and Pathogenesis of Ageing with HIV: Potential Mechanisms and Biomarkers. AIDS 2017, 31 (Suppl. S2), S105–S119. [Google Scholar] [CrossRef] [PubMed]
- Carr, A.; Miller, J.; Law, M.; Cooper, D.A. A Syndrome of Lipoatrophy, Lactic Acidaemia and Liver Dysfunction Associated with HIV Nucleoside Analogue Therapy: Contribution to Protease Inhibitor-Related Lipodystrophy Syndrome. AIDS 2000, 14, F25-32. [Google Scholar] [CrossRef]
- World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection; WHO Guidelines Approved by the Guidelines Review Committee; World Health Organization: Geneva, Switzerland, 2015; ISBN 978-92-4-154905-9.
- Guidelines on the Management of Abnormal Liver Blood Tests. Available online: https://www.researchgate.net/publication/320971732_Guidelines_on_the_management_of_abnormal_liver_blood_tests (accessed on 27 April 2025).
- Argiris, A.; Mathur-Wagh, U.; Wilets, I.; Mildvan, D. Abnormalities of Serum Amylase and Lipase in HIV-Positive Patients. Am. J. Gastroenterol. 1999, 94, 1248–1252. [Google Scholar] [CrossRef]
- Sulkowski, M.S.; Thomas, D.L.; Chaisson, R.E.; Moore, R.D. Hepatotoxicity Associated with Antiretroviral Therapy in Adults Infected with Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. JAMA 2000, 283, 74–80. [Google Scholar] [CrossRef] [PubMed]
- Matthews, G.V.; Manzini, P.; Hu, Z.; Khabo, P.; Maja, P.; Matchaba, G.; Sangweni, P.; Metcalf, J.; Pool, N.; Orsega, S.; et al. Impact of Lamivudine on HIV and Hepatitis B Virus-Related Outcomes in HIV/Hepatitis B Virus Individuals in a Randomized Clinical Trial of Antiretroviral Therapy in Southern Africa. AIDS 2011, 25, 1727–1735. [Google Scholar] [CrossRef] [PubMed]
- Petrovic, L.M. HIV/HCV Co-Infection: Histopathologic Findings, Natural History, Fibrosis, and Impact of Antiretroviral Treatment: A Review Article. Liver Int. 2007, 27, 598–606. [Google Scholar] [CrossRef]
- Tsochatzis, E.A.; Castera, L. Assessing Liver Disease in HIV-HCV Coinfected Patients. Curr. Opin. HIV AIDS 2015, 10, 316–322. [Google Scholar] [CrossRef]
- Thio, C.L.; Seaberg, E.C.; Skolasky, R.; Phair, J.; Visscher, B.; Muñoz, A.; Thomas, D.L. Multicenter AIDS Cohort Study HIV-1, Hepatitis B Virus, and Risk of Liver-Related Mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360, 1921–1926. [Google Scholar] [CrossRef]
- Greub, G.; Ledergerber, B.; Battegay, M.; Grob, P.; Perrin, L.; Furrer, H.; Burgisser, P.; Erb, P.; Boggian, K.; Piffaretti, J.C.; et al. Clinical Progression, Survival, and Immune Recovery during Antiretroviral Therapy in Patients with HIV-1 and Hepatitis C Virus Coinfection: The Swiss HIV Cohort Study. Lancet 2000, 356, 1800–1805. [Google Scholar] [CrossRef] [PubMed]
- Núñez, M.; Lana, R.; Mendoza, J.L.; Martín-Carbonero, L.; Soriano, V. Risk Factors for Severe Hepatic Injury after Introduction of Highly Active Antiretroviral Therapy. J. Acquir. Immune Defic. Syndr. 2001, 27, 426–431. [Google Scholar] [CrossRef]
- de Moura Tomich, L.G.M.; Núñez, M.; Mendes-Correa, M.C. Drug-Induced Liver Injury in Hospitalized HIV Patients: High Incidence and Association with Drugs for Tuberculosis. Ann. Hepatol. 2015, 14, 888–894. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.-X.; Yin, X.-D.; Zhang, Y.; Shao, Q.-H.; Mao, X.-Y.; Hu, W.-J.; Shen, Y.-L.; Zhao, B.; Li, Z.-L. Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database. Front. Pharmacol. 2022, 13, 891336. [Google Scholar] [CrossRef] [PubMed]
- Rajbhandari, R.; Jun, T.; Khalili, H.; Chung, R.T.; Ananthakrishnan, A.N. HBV/HIV Coinfection Is Associated with Poorer Outcomes in Hospitalized Patients with HBV or HIV. J. Viral Hepat. 2016, 23, 820–829. [Google Scholar] [CrossRef]
- Seth, A.; Sherman, K.E. Fatty Liver Disease in Persons With HIV Infection. Top. Antivir. Med. 2019, 27, 75–82. [Google Scholar]
- WMA—The World Medical Association-WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Participants. Available online: https://www.wma.net/policies-post/wma-declaration-of-helsinki/ (accessed on 29 March 2025).
- European Medicines Agency (EMA). Available online: https://www.ema.europa.eu/en/homepage (accessed on 27 April 2025).
- Marin, R.-C.; Bungau, S.G.; Tit, D.M.; Negru, P.A.; Radu, A.-F.; Moleriu, R.D. Immune Recovery among Romanian HIV/AIDS Patients Receiving Darunavir/Ritonavir or Darunavir/Cobicistat Regimens in cART Management: A Three-Year Study. Biomed. Pharmacother. 2023, 161, 114427. [Google Scholar] [CrossRef]
- Marin, R.-C.; Streinu-Cercel, A.; Moleriu, L.C.; Bungau, S.G. Analysis of Virological Response to Therapy and Resistance Profile in Treatment-Experienced and Naive HIV-1 Infected Romanian Patients Receiving Regimens Containing Darunavir Boosted with Ritonavir or Cobicistat. Biomed. Pharmacother. 2022, 150, 113077. [Google Scholar] [CrossRef]
- EACS Guidelines. Available online: https://www.eacsociety.org/guidelines/eacs-guidelines/ (accessed on 29 March 2025).
- Dhanjal, A. Launching the EASL Guidelines App! In EASL-The Home of Hepatology; EASL Office: Geneva, Switzerland, 2024. [Google Scholar]
Parameters | HIV n = 176 | HIV/HBV n = 114 | HIV/HCV n = 97 | HIV/HBV/HCV n = 75 | Statistics | p Value | |
---|---|---|---|---|---|---|---|
Age (years, mean ± SD) | 46.006 ± 11.750 | 45.053 ± 10.865 | 44.371 ± 9.817 | 45.067 ± 12.823 | 1.352 1 | 0.717 1 | |
Age at diagnosis (years, mean ± SD) | 28.540 ± 13.271 | 25.298 ± 13.120 | 27.093 ± 11.476 | 24.160 ± 14.802 | 6.476 1 | 0.091 1 | |
Sex n (%) | Male | 105 (59.66) | 76 (66.67) | 60 (61.86) | 45 (60.00) | 1.588 2 | 0.662 2 |
Female | 71 (40.34) | 38 (33.33) | 37 (38.14) | 30 (40) | |||
Environment n (%) | Rural | 48 (27.27) | 28 (24.56) | 18 (18.56) | 23 (30.67) | 3.869 2 | 0.276 2 |
Urban | 128 (72.73) | 86 (75.44) | 79 (81.44) | 52 (69.33) | |||
Education level n (%) | Illiterate | 3 (1.70) | 2 (1.75) | 2 (2.06) | 2 (2.67) | 25.556 2 | 0.110 2 |
High school | 99 (56.25) | 74 (64.91) | 61 (62.89) | 49 (65.33) | |||
Professional | 7 (3.97) | 14 (12.28) | 11 (11.34) | 8 (10.67) | |||
University | 35 (19.89) | 12 (10.53) | 7 (7.22) | 7 (9.33) | |||
Unknown | 32 (18.18) | 12 (10.52) | 16 (16.50) | 9 (12) | |||
No. of years illness (mean ± SD) | 17.466 ± 7.612 | 19.754 ± 8.204 | 17.278 ± 7.670 | 20.907 ± 8.128 | 14.559 1 | 0.002 1 | |
No. of years of therapy (mean ± SD) | 14.381 ± 6.079 | 16.088 ± 6.382 | 14.351 ± 6.093 | 16.547 ± 6.595 | 9.126 1 | 0.028 1 | |
First HIV-1 RNA viral load (copies/mL) (mean ± SD) | 513,307.858 ± 1.545 × 10+6 | 317,901.579 ± 866,724.689 | 397,283.186 ± 1.270 × 10+6 | 1.150 × 10+6 ± 132,771.892 | 3.532 1 | 0.317 1 | |
CD4 T-cell counts at diagnosis (cells/mm3) (mean ± SD) | 333.443 ± 254.257 | 372.737 ± 256.764 | 369.928 ± 361.502 | 294.360 | 2.138 1 | 0.544 1 | |
Nadir CD4 T-cell counts (cells/mm3) (mean ± SD) | 213.591 ± 186.106 | 214.509 ± 182.966 | 208.464 ± 203.001 | 175.360 ± 159.206 | 2.470 1 | 0.481 1 | |
History of ARVs n (%) | Naive | 9 (5.11) | 6 (5.27) | 11 (11.34) | 4 (5.33) | 4.755 2 | 0.191 2 |
Experienced | 167 (94.89) | 108 (94.73) | 86 (88.66) | 71 (94.67) | |||
No. of ARV regimens (mean ± SD) | 6.506 ± 6.524 | 9.018 ± 8.042 | 7.041 ± 7.331 | 9.480 ± 8.026 | 10.143 1 | 0.017 1 |
Group | Comparison | No. of Years Illness/ p Value | No. of Years Therapy/ p Value | No. of ARV Regimens |
---|---|---|---|---|
HIV | HIV/HBV/HCV | 0.002 | 0.021 | 0.013 |
HIV/HCV | 0.927 | 0.921 | 0.869 | |
HIV/HBV | 0.019 | 0.026 | 0.019 | |
HIV/HBV/HCV | HIV/HCV | 0.004 | 0.046 | 0.036 |
HIV/HBV | 0.299 | 0.728 | 0.682 | |
HIV/HCV | HIV/HBV | 0.034 | 0.065 | 0.059 |
Parameters in n (%) | HIV n = 176 | HIV/HBV n = 114 | HIV/HCV n = 97 | HIV/HBV/HCV n = 75 | Statistics | p Value | |
---|---|---|---|---|---|---|---|
NNRTI | None | 148 (84.09) | 96 (21.00) | 86 (88.65) | 63 (88.66) | 1.251 2 | 0.741 2 |
1 | 28 (15.91) | 18 (15.79) | 11 (11.34) | 12 (16.06) | |||
NRTI | None | 22 (12.52) | 14 (12.28) | 8 (8.25) | 8 (10.65) | 15.504 2 | 0.215 2 |
1 | 19 (10.83) | 21 (18.42) | 9 (9.28) | 11 (14.67) | |||
2 | 133 (75.57) | 77 (67.53) | 75 (77.30) | 54 (72.00) | |||
3 | 2 (1.14) | 1 (0.88) | 2 (2.06) | 2 (2.62) | |||
4 | 0 (0.00) | 1 (0.88) | 3 (3.12) | 0 (0.00) | |||
PI | None | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1.701 2 | 0.637 2 |
1 | 175 (99.41) | 144 (100.00) | 96 (98.99) | 75 (100.00) | |||
2 | 1 (0.57) | 0 (0.00) | 1 (1.03) | 0 (0.00) | |||
II | None | 138 (78.43) | 85 (74.56) | 76 (78.34) | 59 (78.67) | 2.475 2 | 0.871 2 |
1 | 37 (21.00) | 29 (25.45) | 21 (21.65) | 16 (21.30) | |||
EI | None | 174 (98.90) | 113 (99.13) | 96 (98.97) | 75 (100.00) | 0.836 2 | 0.841 2 |
1 | 2 (1.10) | 1 (0.88) | 1 (1.02) | 0 (0.00) |
Parameters in n (%) | HIV n = 176 | HIV/HBV n = 114 | HIV/HCV n = 97 | HIV/HBV/HCV n = 75 | Statistics | p Value | |
---|---|---|---|---|---|---|---|
NNRTI types | EFZ | 1 (0.56) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1.523 2 | 0.677 2 |
ETV | 25 (14.20) | 17 | 11 (11.34) | 11 (14.66) | |||
NRTI types | 3TC | 2 (1.13) | 0 (0.00) | 0 (0.00) | 3 (4.00) | 45.159 2 | 0.465 2 |
3TC + TDF | 0 (0.00) | 0 (0.00) | 1 (1.03) | 0 (0.00) | |||
3TC + ZDV | 18 (10.22) | 13 (11.40) | 11 (11.34) | 9 (12.00) | |||
3TC + ZDV + FTC + TDF | 0 (0.00) | 1 (0.88) | 0 (0.00) | 0 (0.00) | |||
ABC | 1 (0.57) | 0 (0.00) | 0 (0.00) | 0 (0.00) | |||
ABC + 3TC | 84 (47.72) | 43 (37.71) | 46 (47.42) | 33 (44.00) | |||
ABC + 3TC + TDF | 1 (0.57) | 0 (0.00) | 0 (0.00) | 2 (2.66) | |||
ABC + 3TC + ZDV | 1 (0.57) | 0 (0.00) | 2 (2.06) | 0 (0.00) | |||
ABC + TDF | 0 (0.00) | 1 (0.88) | 1 (1.03) | 0 (0.00) | |||
FTC | 3 (1.70) | 0 (0.00) | 2 (2.06) | 0 (0.00) | |||
FTC + TAF | 5 (2.84) | 4 (3.51) | 2 (2.06) | 2 (2.66) | |||
FTC + TDF | 5 (2.84) | 4 (3.51) | 2 (2.06) | 2 (2.66) | |||
TDF | 13 (7.39) | 18 (15.79) | 7 (7.22) | 11 (14.66) | |||
TDF + 3TC | 1 (0.57) | 0 (0.00) | 0 (0.00) | 0 (0.00) | |||
FTC + TAF + ABC + 3TC | 25 (14.20) | 17 (14.91) | 16 (16.49) | 10 (13.33) | |||
PI types | DRV | 175 (99.43) | 114 (100.00) | 96 (98.97) | 75 (100.00) | 1.701 2 | 0.637 2 |
DRV + ATV | 1 (0.57) | 0 (0.00) | 1 (1.03) | 0 (0.00) | |||
II types | DTG | 12 (6.82) | 19 (16.66) | 8 (8.24) | 3 (4.00) | 12.295 2 | 0.006 2 |
RAL | 27 (15.34) | 10 (8.77) | 13 (13.40) | 13 (17.33) | |||
EI types | MVC | 2 (1.13) | 1 (0.88) | 1 (1.03) | 0 (0.00) | 0.836 2 | 0.841 2 |
Booster | RTV | 143 (81.25) | 95 (83.33) | 82 (84.53) | 64 (85.33) | 0.843 2 | 0.839 2 |
COBI | 33 (18.75) | 19 (16.66) | 15 (15.46) | 11 (14.66) |
Parameters | HIV n = 176 | HIV/HBV n = 114 | HIV/HCV n = 97 | HIV/HBV/HCV n = 75 | Statistics | p Value | ||
---|---|---|---|---|---|---|---|---|
CD4 T-cell counts (cells/mm3) (mean ± SD) | 563.114 ± 320.227 | 571.386 ± 302.299 | 545.928 ± 325.586 | 570.387 ± 324.183 | 0.622 1 | 0.891 1 | ||
CD8 T-cell counts (cells/mm3) (mean ± SD) | 862.241 ± 423.662 | 909.728 ± 391.282 | 925.361 ± 610.541 | 764.653 ± 357.669 | 6.865 1 | 0.076 1 | ||
CD4/CD8 Ratio (mean ± SD) | 0.848 ± 0.727 | 0.757 ± 0.574 | 0.962 ± 1.859 | 0.888 ± 0.699 | 2.344 1 | 0.504 1 | ||
CD4 cell counts categories n (%) | 0–199 | 33 (18.75) | 21 (18.42) | 21 (21.65) | 15 (20.00) | 5.108 2 | 0.825 2 | |
200–349 | 13 (7.40) | 8 (7.02) | 7 (7.22) | 7 (9.33) | ||||
350–499 | 40 (22.72) | 17 (14.91) | 20 (20.62) | 11 (14.67) | ||||
>500 | 90 (51.14) | 68 (59.65) | 49 (50.51) | 42.(56.00) | ||||
CD4/CD8 ratio categories n (%) | ≤0.50 | 51 (29.82) | 42 (40.54) | 35 (36.08) | 30 (40.54) | 5.584 2 | 0.471 2 | |
0.51–0.99 | 76 (44.44) | 38 (33.62) | 38 (39.17) | 24 (32.43) | ||||
≥1 | 44 (27.73) | 33 (29.20) | 24 (24.74) | 20 (27.02) | ||||
HIV-1 RNA viral load categories n (%) | 0 | 133 (75.56) | 87 (76.32) | 77 (79.38) | 63 (84.00) | 5.544 2 | 0.785 2 | |
<50 | 1 (0.57) | 0 (0.00) | 0 (0.00) | 0 (0.00) | ||||
50–999 | 24 (13.63) | 17 (14.91) | 13 (13.40) | 5 (6.67) | ||||
˃1000 | 18 (10.22) | 10 (8.77) | 7 (7.21) | 7 (9.33) | ||||
Stage of disease n (%) | A1 | 6 (3.40) | 3 (2.63) | 2 (2.06) | 0 (0.00) | 34.040 2 | 0.084 2 | |
A2 | 22 (12.50) | 4 (3.50) | 5(5.15) | 2 (2.67) | ||||
A3 | 6 (3.40) | 1 (0.88) | 3 (3.10) | 4 (5.33) | ||||
B1 | 1 (0.57) | 0 (0.00) | 1 (1.03) | 0 (0.00) | ||||
B2 | 22 (12.50) | 14 (12.81) | 11 (11.34) | 4 (5.53) | ||||
B3 | 24 (13.64) | 17 (14.91) | 14 (14.43) | 6 (8.00) | ||||
C1 | 2 (1.14) | 0 (0.00) | 0 (0.00) | 1 (1.33) | ||||
C2 | 9 (5.11) | 7 (6.14) | 3 (0.93) | 3 (4.00) | ||||
C3 | 84 (47.72) | 68 (59.65) | 58 (59.80) | 55 (73.33) |
Parameters | CD4 T-Cell Counts (Cells/mm3) | CD8 T-Cell Counts (Cells/mm3) | CD4/CD8 Ratio | HIV-1 RNA Viral Load (Copies/mL) | |
---|---|---|---|---|---|
p Value Mann–Whitney U Test | |||||
HIV n = 176 | Naive | 0.818 | 0.393 | 0.434 | 0.327 |
Experienced | |||||
HIV/HBV n = 114 | Naïve | 0.625 | 0.450 | 0.522 | 0.628 |
Experienced | |||||
HIV/HCV n = 97 | Naïve | 0.055 | 0.098 | 0.629 | 0.539 |
Experienced | |||||
HIV/HBV/HCV n = 75 | Naïve | 0.225 | 0.183 | 0.563 | 0.614 |
Experienced |
Variables | CD4 Count (Cells/mm3) | HIV1-RNA Load (Copies/mL) | ||
---|---|---|---|---|
Pearson’s r | p Value | Pearson’s r | p Value | |
Age | 0.156 | 0.038 | 0.099 | 0.189 |
Age at diagnosis | 0.054 | 0.478 | 0.052 | 0.491 |
No. of years of illness | 0.147 | 0.051 | 0.063 | 0.408 |
No. of years of therapy | 0.135 | 0.073 | 0.048 | 0.529 |
First RNA (copies/mL) | 0.023 | 0.762 | −0.023 | 0.760 |
CD4 at diagnosis (cells/mm3) | 0.067 | 0.373 | −0.096 | 0.204 |
Nadir CD4 | −0.035 | 0.643 | −0.071 | 0.348 |
No. of ARV regimens | −0.086 | 0.256 | 0.056 | 0.462 |
Variables | CD4 Count (Cells/mm3) | HIV1-RNA Load (Copies/mL) | ||
---|---|---|---|---|
Pearson’s r | p Value | Pearson’s r | p Value | |
Age | 0.063 | 0.506 | −0.057 | 0.546 |
Age at diagnosis | 0.172 | 0.067 | 0.021 | 0.824 |
Number of years of illness | −0.192 | 0.041 | −0.109 | 0.247 |
Number of years of therapy | −0.197 | 0.035 | −0.044 | 0.645 |
First HIV1-RNA load (copies/mL) | 0.100 | 0.289 | −0.031 | 0.743 |
CD4 at diagnosis (cells/mm3) | 0.062 | 0.512 | 0.136 | 0.148 |
Nadir CD4 (cells/mm3) | 0.044 | 0.645 | 0.088 | 0.352 |
No. of ARV regimens | −0.128 | 0.176 | −0.083 | 0.379 |
Variables | CD4 Count (Cells/mm3) | HIV1-RNA Load (Copies/mL) | ||
---|---|---|---|---|
Pearson’s r | p Value | Pearson’s r | p Value | |
Age | 0.176 | 0.087 | 0.053 | 0.611 |
Age at diagnosis | 0.074 | 0.475 | 0.019 | 0.853 |
Number of years of illness | 0.115 | 0.266 | 0.039 | 0.708 |
Number of years of therapy | −0.003 | 0.979 | 0.099 | 0.339 |
First RNA (copies/mL) | 0.008 | 0.937 | 0.009 | 0.929 |
CD4 at diagnosis (cells/mm3) | 0.129 | 0.209 | −0.069 | 0.502 |
Nadir CD4 (cells/mm3) | 0.268 | 0.008 | −0.103 | 0.318 |
No. of ARV regimens | −0.038 | 0.714 | 0.069 | 0.506 |
Variables | CD4 Count (Cells/mm3) | HIV1-RNA Load (Copies/mL) | ||
---|---|---|---|---|
Pearson’s r | p Value | Pearson’s r | p Value | |
Age | 0.020 | 0.864 | −0.053 | 0.653 |
Age at diagnosis | 0.063 | 0.592 | −0.130 | 0.268 |
Number of years of illness | −0.083 | 0.480 | 0.153 | 0.191 |
Number of years of therapy | −0.217 | 0.041 | 0.046 | 0.694 |
First HIV1-RNA load (copies/mL) | −0.044 | 0.707 | −0.072 | 0.538 |
CD4 at diagnosis (cells/mm3) | −0.007 | 0.949 | 0.229 | 0.049 |
Nadir CD4 (cells/mm3) | 0.091 | 0.436 | 0.084 | 0.472 |
No. of ARV regimens | −0.112 | 0.340 | −0.007 | 0.953 |
Parameters | HIV n = 176 | HIV/HBV n = 114 | HIV/HCV n = 97 | HIV/HBV/HCV n = 75 | Statistics | p Value |
---|---|---|---|---|---|---|
ALT (IU/L) | 53.158 ± 48.904 | 25.256 ± 8.873 | 27.823 ± 21.787 | 17.840 ± 14.321 | 198.488 1 | <0.001 1 |
AST (IU/L) | 35.938 ± 26.507 | 28.693 ± 9.372 | 34.427 ± 27.151 | 36.587 ± 48.460 | 5.081 1 | 0.166 1 |
AST/ALP | 0.745 ± 0.198 | 1.141 ± 0.150 | 1.280 ± 0.214 | 2.009 ± 0.589 | 344.494 1 | <0.001 1 |
GGT (IU/L) | 20.616 ± 10.796 | 34.851 ± 11.334 | 46.396 ± 14.599 | 167.947 ± 294.338 | 344.211 1 | |
Amylase (IU/L) | 48.723 ± 11.250 | 70.667 ± 7.499 | 77.021 ± 11.283 | 125.813 ± 44.156 | 343.869 1 | |
Lipase (IU/L) | 65.689 ± 66.712 | 125.447 ± 57.348 | 190.521 ± 86.039 | 642.987 ± 209.566 | 336.872 1 | |
Direct bilirubin (mg/dL) | 0.171 ± 0.062 | 0.254 ± 0.061 | 0.305 ± 0.065 | 0.563 ± 0.372 | 303.898 1 | |
Indirect bilirubin (mg/dL) | 0.210 ± 0.095 | 0.374 ± 0.083 | 0.449 ± 0.099 | 1.145 ± 0.968 | 332.998 1 | |
Total bilirubin (mg/dL) | 0.418 ± 0.112 | 0.612 ± 0.078 | 0.683 ± 0.128 | 1.504 ± 1.096 | 336.035 1 | |
ALP (IU/L) | 56.045 ± 11.983 | 76.123 ± 8.226 | 83.938 ± 13.099 | 133.360 ± 50.955 | 344.105 1 |
Parameter | HIV vs. HIV/HBV/HCV | HIV vs. HIV/HCV | HIV vs. HIV/HBV | HIV/HBV/HCV vs. HIV/HBV | HIV/HBV/HCV vs. HIV/HCV | HIV/HCV vs. HIV/HBV |
---|---|---|---|---|---|---|
p Value | ||||||
ALT | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.335 |
AST | 0.089 | 0.125 | 0.070 | 0.909 | 0.794 | 0.866 |
AST/ALT | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.008 |
GGT | 0.009 | |||||
Amylase | 0.010 | |||||
Lipase | 0.109 | |||||
Direct bilirubin | <0.001 | |||||
Indirect bilirubin | 0.002 | |||||
Total bilirubin | 0.011 | |||||
ALP | 0.009 |
Parameters | HIV/HBV/HCV vs. HIV | HIV/HBV vs. HIV | HIV/HCV vs. HIV |
---|---|---|---|
ALT | OR = 8.2, p < 0.001 OR∈[2.86; 23.61] | OR = 52.3, p < 0.001 OR∈[7.12; 384.09] | OR = 4.47, p < 0.001 OR∈[2.1; 9.5] |
AST | OR = 2.29, p = 0.012 OR∈[1.18; 4.43] | OR = 1.97, p = 0.014 OR∈[1.14; 3.41] | OR = 1.66, p = 0.048 OR∈[1.09; 2.93] |
AST/ALT ratio | OR > 50, p < 0.001 OR∈[20.06; 662.2] | OR > 50, p < 0.001 OR∈[45.95; 702.47] | OR > 50, p < 0.001 OR∈[39.49; 789.5] |
GGT | OR > 50, p < 0.001 OR∈[23.13; 662.26] | OR = 11.74, p < 0.001 OR∈[4.39; 31.39] | OR > 50, p < 0.001 OR∈[35.96; 265.3] |
Amylase | OR > 50, p < 0.001 OR∈[30.1; 835.8] | OR > 50, p < 0.001 | OR > 50, p < 0.001 |
Lipase | OR > 50, p < 0.001 OR∈[14.38; 386.82] | OR > 50, p < 0.001 OR∈[21.87; 584.59] | R > 50, p < 0.001 OR∈[18.4; 493.31] |
Direct bilirubin | OR = 12.07, p = 0.029 OR∈[1.573; 254.58] | OR > 50, p < 0.001 | OR > 50, p < 0.001 |
Indirect bilirubin | OR > 50, p < 0.001 OR∈[8.9; 250.41] | OR > 50, p < 0.001 | OR > 50, p < 0.001 |
Total bilirubin | OR > 50, p < 0.001 OR∈[13.5; 375.99] | OR > 50, p < 0.001 | OR > 50, p < 0.001 |
ALP | OR > 50, p < 0.001 OR∈[6.28; 179.46] | OR > 50, p < 0.001 | OR > 50, p < 0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marin, R.-C.; Tit, D.M.; Bungău, G.; Moleriu, R.D. The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study. Pharmaceuticals 2025, 18, 688. https://doi.org/10.3390/ph18050688
Marin R-C, Tit DM, Bungău G, Moleriu RD. The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study. Pharmaceuticals. 2025; 18(5):688. https://doi.org/10.3390/ph18050688
Chicago/Turabian StyleMarin, Ruxandra-Cristina, Delia Mirela Tit, Gabriela Bungău, and Radu Dumitru Moleriu. 2025. "The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study" Pharmaceuticals 18, no. 5: 688. https://doi.org/10.3390/ph18050688
APA StyleMarin, R.-C., Tit, D. M., Bungău, G., & Moleriu, R. D. (2025). The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study. Pharmaceuticals, 18(5), 688. https://doi.org/10.3390/ph18050688